Upstream Bio posts VIBRANT Phase 2 results for verekitug in nasal polyps
Results for the completed Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps were posted on September 18, 2026.
Upstream Bio's update this week centers on results reporting for its Phase 2 nasal polyps study.
- Verekitug (UPB-101), a subcutaneous drug tested in a Phase 2 trial called "VIBRANT," has completed with primary completion recorded as July 7, 2025 and results first posted September 18, 2026. The study enrolled 81 participants who received either verekitug or placebo every 12 weeks for 24 weeks.1 Its main goal was measuring change from baseline in Nasal Polyp Score, a physician-reported scoring system estimating the extent or severity of nasal polyps based on nasal endoscopy assessments,1 at Week 24.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.